Sumatriptan vs. Rizatriptan: Triptan Comparison for PI Migraine

Amar Lunagaria — Co-Founder & Chief Pharmacist, LienScripts | March 3, 2026 | 8 min read

Sumatriptan and rizatriptan are the two most-prescribed triptans for post-traumatic migraine. Both are 5-HT1B/1D serotonin receptor agonists, but they differ significantly in onset speed, formulation options, and drug interactions — differences that matter for personal injury patients with acute migraine burden after whiplash, TBI, or concussion.

Sumatriptan vs. Rizatriptan: Triptan Comparison for PI Migraine

Sumatriptan and rizatriptan are both selective 5-HT1B/1D receptor agonists (triptans) that abort acute migraine attacks by constricting dilated meningeal blood vessels and blocking trigeminal nerve pain transmission. They are the two most commonly prescribed triptans in the United States, and they are frequently dispensed under pharmacy liens for personal injury patients who develop post-traumatic migraine after motor vehicle accidents, falls, and other head and neck trauma. The key clinical differences — onset speed, formulation range, and drug interactions — determine which triptan a treating physician selects for a given patient.

• Sumatriptan offers the widest formulation range of any triptan: oral tablets, nasal spray, subcutaneous injection (Imitrex, Zembrace SymTouch), and transdermal patch
• Rizatriptan (Maxalt) has a faster oral onset (~30 minutes vs. ~60 minutes for oral sumatriptan), making it the preferred oral triptan for rapid relief
• Sumatriptan subcutaneous injection provides the fastest relief of any triptan (10-15 minutes) — critical for severe, rapidly escalating post-traumatic migraine attacks
• Rizatriptan's orally disintegrating tablet (Maxalt-MLT) dissolves on the tongue without water, making it essential for patients with migraine-associated nausea who cannot swallow
• Both triptans carry the same cardiovascular contraindication: they cannot be used in patients with coronary artery disease, uncontrolled hypertension, or prior stroke

[!KEY] The prescribing of any triptan for a personal injury patient documents migraine-pattern headaches — not simple tension headaches — which supports the severity and neurological nature of the head or neck injury sustained in the accident.

Why Triptans Matter in Personal Injury Cases

Post-traumatic migraine is one of the most common neurological consequences of whiplash, traumatic brain injury (TBI), and concussion. The International Classification of Headache Disorders (ICHD-3) classifies post-traumatic headache as a secondary headache disorder attributed to trauma, and when the headache phenotype meets migraine criteria — unilateral, pulsating, moderate-to-severe, with nausea, photophobia, or phonophobia — the treating physician diagnoses post-traumatic migraine.

The distinction between migraine and tension-type headache is clinically significant and legally relevant. Defense counsel routinely argue that post-accident headaches are benign tension headaches that resolve spontaneously. A triptan prescription directly contradicts this argument: triptans are FDA-approved exclusively for migraine. They have no indication for tension headache, and no treating physician would prescribe a triptan for a simple tension headache. As Amar Lunagaria, PharmD, LienScripts' Chief Pharmacist explains, "When a triptan appears on a pharmacy lien record, it is clinical evidence that the treating physician diagnosed a migraine disorder — not a benign headache — and that diagnosis is anchored to the accident."

LienScripts generates a POGOS (Pharmacy-Organized General Occurrence Summary) report for every case, providing pharmacist-signed documentation that identifies triptan dispensing records and contextualizes them within the full medication timeline for demand packages.

Head-to-Head Comparison

Sumatriptan: The Formulation Versatility Advantage

Sumatriptan's defining clinical strength is its unmatched formulation range. No other triptan is available in as many delivery routes, which allows treating physicians to match the administration method to the patient's specific clinical scenario.

Oral Tablets (25mg, 50mg, 100mg)

Standard sumatriptan tablets are the most commonly prescribed triptan formulation overall. The 100mg dose provides the strongest oral efficacy, with approximately 60-65% of patients achieving pain relief within two hours. For PI patients with predictable migraine patterns — migraines that build gradually over 30-60 minutes — oral sumatriptan at the 100mg dose is effective and straightforward.

The limitation: oral sumatriptan has a relatively slow onset of approximately 60 minutes for meaningful relief. Patients experiencing rapidly escalating attacks, or patients with severe nausea who cannot keep a tablet down, require alternative routes.

Nasal Spray (5mg, 20mg)

Sumatriptan nasal spray provides faster absorption through the nasal mucosa, with onset typically in 15-30 minutes. The 20mg nasal spray is particularly useful for PI patients who experience nausea as a prominent migraine feature — the drug is absorbed without requiring swallowing or gastrointestinal transit.

The nasal route also bypasses first-pass hepatic metabolism, potentially providing more predictable bioavailability in patients with gastroparesis or delayed gastric emptying during migraine attacks.

Subcutaneous Injection (4mg, 6mg — Imitrex, Zembrace SymTouch)

The subcutaneous injection is the fastest-acting triptan formulation available by any route. Sumatriptan 6mg SC provides meaningful pain relief in 10-15 minutes, with complete pain freedom at two hours in approximately 50-60% of patients. The Zembrace SymTouch autoinjector (3mg) provides a lower-dose option designed for patients who respond to sumatriptan but experience side effects at 6mg.

For PI patients with severe, rapidly escalating post-traumatic migraine — especially those with TBI-associated migraines that can peak within minutes — the subcutaneous injection is sometimes the only formulation that provides relief fast enough to prevent progression to a full-blown, hours-long attack.

PI documentation value: A prescription for sumatriptan SC injection documents migraine severity that oral medications cannot adequately manage. The clinical decision to prescribe an injectable triptan reflects the treating physician's assessment that the patient's migraine attacks are severe, rapid-onset, and functionally disabling enough to warrant the fastest available intervention.

[!KEY] A sumatriptan subcutaneous injection prescription is among the strongest single-medication records documenting migraine severity — it reflects a clinical determination that the patient's attacks are too severe or too rapid for oral or nasal treatment to provide adequate relief.

Rizatriptan: The Speed and Convenience Advantage

Rizatriptan's clinical niche is defined by two features: faster oral onset than any other oral triptan, and the availability of an orally disintegrating tablet that dissolves on the tongue.

Faster Oral Onset (~30 Minutes)

Among oral triptan formulations, rizatriptan 10mg consistently demonstrates the fastest time to meaningful pain relief — approximately 30 minutes, compared to approximately 60 minutes for oral sumatriptan 100mg. This speed advantage is driven by rizatriptan's pharmacokinetic profile: faster absorption, higher oral bioavailability (approximately 45% vs. 14% for oral sumatriptan), and rapid achievement of peak plasma concentrations.

For PI patients who need oral triptan efficacy without the delay of sumatriptan's slower onset, rizatriptan is the evidence-based choice. The 30-minute onset can be the difference between aborting a migraine during the aura phase and enduring a full attack lasting 4-72 hours.

Maxalt-MLT: The Orally Disintegrating Tablet

The Maxalt-MLT formulation dissolves on the tongue in seconds without water. This is not a convenience feature — it is a clinically critical formulation for PI patients with severe migraine-associated nausea.

During an acute migraine attack, up to 80% of patients experience nausea, and approximately 30% experience vomiting. For these patients, swallowing a conventional tablet during an attack is unreliable — the tablet may be vomited before absorption, or the gastroparesis that accompanies migraine may prevent adequate absorption even if the tablet is retained. The Maxalt-MLT bypasses this problem entirely by dissolving on the tongue and being absorbed through the oral mucosa and saliva.

PI documentation value: A Maxalt-MLT prescription documents that the patient's post-traumatic migraines are accompanied by nausea or vomiting significant enough that the treating physician selected a formulation specifically designed for patients who cannot swallow during attacks.

The Propranolol Interaction: A Critical Clinical Consideration

Propranolol is one of the most commonly prescribed migraine preventive medications, and it is frequently used in PI patients who develop chronic post-traumatic migraine requiring both preventive and acute therapy. This creates a significant drug interaction consideration that differentiates sumatriptan from rizatriptan.

Rizatriptan + propranolol: Propranolol inhibits the MAO-A enzyme that metabolizes rizatriptan, increasing rizatriptan plasma concentrations by approximately 70%. When a patient is taking propranolol, the rizatriptan dose must be reduced from 10mg to 5mg. This mandatory dose reduction may reduce the efficacy of rizatriptan for patients who need the full 10mg dose for adequate migraine relief.

Sumatriptan + propranolol: Sumatriptan is not primarily metabolized by MAO-A in a clinically significant way at standard doses, and no dose adjustment is required when co-prescribed with propranolol.

This interaction often determines the triptan selection in PI patients receiving propranolol for migraine prevention. A neurologist managing a PI patient on propranolol who needs the most effective acute triptan therapy may choose sumatriptan specifically to avoid the rizatriptan dose reduction.

[!KEY] For PI patients taking propranolol for migraine prevention, sumatriptan avoids the mandatory dose reduction required with rizatriptan — a clinical consideration that often determines triptan selection in patients on combination preventive/acute therapy.

Cardiovascular Contraindications: Shared Across All Triptans

All triptans — including sumatriptan and rizatriptan — are contraindicated in patients with:

• Coronary artery disease (CAD) or a history of myocardial infarction
• Cerebrovascular disease or a history of stroke or TIA
• Uncontrolled hypertension
• Peripheral vascular disease
• Hemiplegic or basilar migraine subtypes

This contraindication is a class effect related to the 5-HT1B receptor's presence on coronary arteries, where agonism causes vasoconstriction. For PI patients with pre-existing cardiovascular disease, triptans are not an option, and treating physicians must use alternative acute treatments such as gepants (ubrogepant, rimegepant), lasmiditan, or NSAIDs.

The contraindication is not specific to either sumatriptan or rizatriptan — it applies equally to both and to all seven FDA-approved triptans.

Which Triptan for Which PI Patient?

Choose sumatriptan when:

• The patient needs the fastest possible relief and a subcutaneous injection is appropriate (severe, rapid-onset attacks)
• The patient is concurrently taking propranolol for migraine prevention and needs full-dose triptan therapy without interaction
• The treating physician wants formulation flexibility — the ability to start with oral and escalate to nasal or injectable if oral therapy proves insufficient
• The patient has attacks that vary in severity and may benefit from dose titration across the 25mg, 50mg, and 100mg oral range

Choose rizatriptan when:

• Speed of oral onset is the priority — the patient needs the fastest-acting oral triptan available (~30 minutes)
• The patient experiences severe nausea or vomiting during migraine attacks and needs an orally disintegrating tablet (Maxalt-MLT) that dissolves without water
• The patient's migraines are moderate severity and respond well to oral therapy but need faster onset than oral sumatriptan provides
• The patient is not taking propranolol (or accepts the 5mg dose reduction if they are)

Consider both (sequential trial) when:

• The patient has not previously tried triptans and the physician wants to assess individual response
• First-line triptan therapy was partially effective and the physician wants to trial the alternative before escalating to a different drug class

What Attorneys Should Know

Triptan Prescribing = Migraine Diagnosis

The single most important fact about triptan prescriptions in a PI case is that they document a migraine diagnosis. Triptans have no indication for tension headache, cluster headache, or generic "head pain." When a treating physician prescribes sumatriptan or rizatriptan, that prescription is a clinical determination that the patient's headache meets the diagnostic criteria for migraine — a specific neurological condition with defined pathophysiology.

Formulation Escalation Documents Severity

A patient who starts on oral sumatriptan 50mg and is later prescribed sumatriptan 6mg SC injection has a pharmacy record that documents escalating migraine severity. The treating physician determined that oral therapy was insufficient and that injectable rescue was necessary. This escalation pattern is powerful evidence of worsening or refractory post-traumatic migraine.

Refill Frequency Documents Chronicity

Monthly triptan refills create an objective pharmacy timeline of ongoing migraine burden. A patient refilling rizatriptan 10mg every month for 12 months has 12 documented months of migraine-frequency headaches requiring acute pharmacotherapy. This timeline is generated automatically from pharmacy dispensing records and is not dependent on patient self-report.

Conclusion

Sumatriptan and rizatriptan are both effective, well-established triptans for post-traumatic migraine in personal injury patients. Sumatriptan's advantage is formulation versatility — particularly the subcutaneous injection for severe attacks and the lack of propranolol interaction. Rizatriptan's advantage is oral speed and the Maxalt-MLT formulation for patients with migraine-associated nausea. The choice between them is a clinical decision that documents specific features of the patient's migraine presentation.

For lien-based triptan coverage at $0 upfront cost for qualified personal injury patients, contact LienScripts or visit the attorney portal.

Related Resources

• CGRP Medications: A Complete Guide for Personal Injury
• Qulipta vs. Nurtec ODT: Which CGRP Gepant Is Right for PI Patients?
• Topiramate vs. Gabapentin for Post-Traumatic Headaches
• Why PI Patients Often Need Multiple Medications
• What Are Medication Liens?